HISTOGENICS CORPORATION (NASDAQ:HSGX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September18, 2017, Gloria Matthews, DVM, Ph.D., DAVCS notified Histogenics Corporation (the “Company”) of her resignation as the Company’s Chief Medical Officer. Dr.Matthews’ resignation will become effective as of September29, 2017. Dr.Matthews’ resigned to pursue a senior executive opportunity at a large non-competitive biopharmaceutical firm, and not due to any disagreement with the Company’s strategy, operations, financials, policies or procedures.

The Company has commenced a comprehensive search for a new Chief Medical Officer with a leading executive search firm. Dr.Matthews’ is working with the Company’s management team and board of directors to jointly design a transition plan. Dr.Matthews will continue to advise the Company as the Chairperson of the Company’s newly created Clinical Advisory Board.

About HISTOGENICS CORPORATION (NASDAQ:HSGX)

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient’s own cartilage cells through a series of tissue engineering processes. The patient’s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company’s Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.